Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease

Forskningsoutput: TidskriftsbidragÖversiktsartikel


Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, noncontinuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available nonoral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI) and the Rivastigmine patch. Here we aim to provide a concise review of these current therapies and discuss ongoing and future developments of continuous non-oral pharmacological dopaminergic therapies in PD.


  • Daniel J. Van Wamelen
  • Sotirios Grigoriou
  • K. Ray Chaudhuri
  • Per Odin
Enheter & grupper
Externa organisationer
  • King's College London
  • King's College Hospital
  • Radboud University Nijmegen
  • Lund University

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurovetenskaper


Sidor (från-till)S65-S72
TidskriftJournal of Parkinson's Disease
Utgåva nummers1
StatusPublished - 2018
Peer review utfördJa